Detailed information for compound 172212

Basic information

Technical information
  • TDR Targets ID: 172212
  • Name: (E)-N,2-dimethyl-3-[3-(trifluoromethyl)phenyl ]prop-2-enamide
  • MW: 243.225 | Formula: C12H12F3NO
  • H donors: 1 H acceptors: 1 LogP: 2.88 Rotable bonds: 4
    Rule of 5 violations (Lipinski): 1
  • SMILES: CNC(=O)/C(=C/c1cccc(c1)C(F)(F)F)/C
  • InChi: 1S/C12H12F3NO/c1-8(11(17)16-2)6-9-4-3-5-10(7-9)12(13,14)15/h3-7H,1-2H3,(H,16,17)/b8-6+
  • InChiKey: QVZSYACQIDPBSG-SOFGYWHQSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • (E)-N,2-dimethyl-3-[3-(trifluoromethyl)phenyl]-2-propenamide
  • (E)-N,2-dimethyl-3-[3-(trifluoromethyl)phenyl]acrylamide
  • 93040-66-5
  • BRN 6510048
  • CINNAMAMIDE, alpha,N-DIMETHYL-m-(TRIFLUOROMETHYL)-
  • alpha,N-Dimethyl-m-(trifluoromethyl)cinnamamide

Targets

Known targets for this compound

No curated genes were found associated with this compound

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Echinococcus granulosus SWI:SNF matrix associated 0.1142 1 1
Leishmania major hypothetical protein, conserved 0.0406 0 0.5
Trypanosoma brucei mitochondrial RNA binding complex 1 subunit 0.0406 0 0.5
Leishmania major hypothetical protein, conserved 0.0406 0 0.5
Toxoplasma gondii SWIB/MDM2 domain-containing protein 0.1142 1 1
Trypanosoma cruzi Zn-finger in Ran binding protein and others/FYVE zinc finger, putative 0.0406 0 0.5
Leishmania major hypothetical protein, conserved 0.0406 0 0.5
Echinococcus multilocularis SWI:SNF matrix associated 0.1142 1 1
Trypanosoma brucei hypothetical protein, conserved 0.0406 0 0.5
Schistosoma mansoni brg-1 associated factor 0.1142 1 1
Echinococcus multilocularis Upstream activation factor subunit UAF30 0.1142 1 1
Loa Loa (eye worm) brahma associated protein 0.1142 1 1
Leishmania major hypothetical protein, conserved 0.0406 0 0.5
Trypanosoma brucei hypothetical protein, conserved 0.0406 0 0.5
Toxoplasma gondii DNA topoisomerase domain-containing protein 0.1142 1 1
Trypanosoma cruzi hypothetical protein, conserved 0.0406 0 0.5
Trypanosoma cruzi hypothetical protein, conserved 0.0406 0 0.5
Trypanosoma cruzi mitochondrial RNA binding complex 1 subunit, putative 0.0406 0 0.5
Plasmodium vivax hypothetical protein, conserved 0.1142 1 0.5
Leishmania major hypothetical protein, conserved 0.0406 0 0.5
Brugia malayi SWIB/MDM2 domain containing protein 0.1142 1 1
Trypanosoma cruzi WLM domain containing protein, putative 0.0406 0 0.5
Trypanosoma cruzi Zn-finger in Ran binding protein and others, putative 0.0406 0 0.5
Trypanosoma cruzi mitochondrial RNA binding complex 1 subunit, putative 0.0406 0 0.5
Trypanosoma brucei Zn-finger in Ran binding protein and others/FYVE zinc finger, putative 0.0406 0 0.5
Echinococcus multilocularis SWI:SNF matrix associated 0.1142 1 1
Echinococcus granulosus Upstream activation factor subunit UAF30 0.1142 1 1
Loa Loa (eye worm) SWIB/MDM2 domain-containing protein 0.1142 1 1
Trypanosoma cruzi Zn-finger in Ran binding protein and others, putative 0.0406 0 0.5
Schistosoma mansoni hypothetical protein 0.1142 1 1
Echinococcus multilocularis SWI:SNF matrix associated 0.1142 1 1
Schistosoma mansoni hypothetical protein 0.1142 1 1
Trypanosoma cruzi hypothetical protein, conserved 0.0406 0 0.5
Brugia malayi brahma associated protein 60 kDa 0.1142 1 1
Plasmodium falciparum SWIB/MDM2 domain-containing protein 0.1142 1 1
Schistosoma mansoni hypothetical protein 0.1142 1 1
Plasmodium falciparum SWIB/MDM2 domain-containing protein 0.1142 1 1
Chlamydia trachomatis SWIB complex protein 0.1142 1 0.5
Trypanosoma cruzi WLM domain containing protein, putative 0.0406 0 0.5
Trichomonas vaginalis conserved hypothetical protein 0.1142 1 0.5
Chlamydia trachomatis DNA topoisomerase I 0.1142 1 0.5
Onchocerca volvulus 0.1142 1 1
Plasmodium vivax SWIB/MDM2 domain-containing protein, putative 0.1142 1 0.5

Activities

Activity type Activity value Assay description Source Reference
ED50 (functional) = 68.8 mg kg-1 Anticonvulsant activity against N-sulfamoylhexahydrozepine (10 mice were used per dose, ip) ChEMBL. 3965710
ED50 (functional) = 68.8 mg kg-1 Anticonvulsant activity against N-sulfamoylhexahydrozepine (10 mice were used per dose, ip) ChEMBL. 3965710
ED50 (functional) = 75 mg kg-1 Effective dose against Mice ataxia, ip administration ChEMBL. 3965710
ED50 (functional) = 75 mg kg-1 Effective dose against Mice docility, ip administration ChEMBL. 3965710
ED50 (functional) = 75 mg kg-1 Effective dose against Mice ataxia, ip administration ChEMBL. 3965710
ED50 (functional) = 75 mg kg-1 Effective dose against Mice docility, ip administration ChEMBL. 3965710
ED50 (functional) > 100 mg kg-1 Effective dose against loss of righting reflex in mice (10 mice per dose, ip) ChEMBL. 3965710
ED50 (functional) > 100 mg kg-1 Effective dose against loss of righting reflex in mice (10 mice per dose, ip) ChEMBL. 3965710
LD50 (ADMET) = 300 mg kg-1 Lethal dose was obtained by 2-h post administration (ip), using four male Royal Hart Wistar rats ChEMBL. 3965710
ND50 (functional) > 75 mg kg-1 Ability to produce neurological deficit in the rotorod test (10 mice were used per dose, ip) ChEMBL. 3965710
ND50 (functional) > 75 mg kg-1 Ability to produce neurological deficit in the rotorod test (10 mice were used per dose, ip) ChEMBL. 3965710
RD50 (functional) = 24.7 mg kg-1 Ability to reinduce anesthesia (70 mg/kg, iv) following recovery of loss of righting reflex obtained with hexobarbital. ChEMBL. 3965710
RD50 (functional) = 24.7 mg kg-1 Ability to reinduce anesthesia (70 mg/kg, iv) following recovery of loss of righting reflex obtained with hexobarbital. ChEMBL. 3965710
Sleep ratio (functional) = 0.3 Ratio of the oral dose of the test compound relative to that of methaqualone (15 mg/kg, po) to induce sleep in Cebus monkey ChEMBL. 3965710

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.